ID   HELZ2_HUMAN             Reviewed;        2649 AA.
AC   Q9BYK8; Q3C2G2; Q4VXQ1; Q8TEF3; Q96ND3; Q9C094;
DT   30-APR-2003, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 6.
DT   12-APR-2017, entry version 162.
DE   RecName: Full=Helicase with zinc finger domain 2;
DE   AltName: Full=ATP-dependent helicase PRIC285;
DE   AltName: Full=Helicase with zinc finger 2, transcriptional coactivator;
DE   AltName: Full=PPAR-alpha-interacting complex protein 285;
DE   AltName: Full=PPAR-gamma DNA-binding domain-interacting protein 1;
DE            Short=PDIP1;
DE            Short=PPAR-gamma DBD-interacting protein 1;
DE   AltName: Full=Peroxisomal proliferator-activated receptor A-interacting complex 285 kDa protein;
DE            EC=3.6.4.-;
GN   Name=HELZ2; Synonyms=KIAA1769, PRIC285;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS ASN-788;
RP   ARG-1123; LEU-2016 AND GLU-2049.
RX   PubMed=12189208; DOI=10.1073/pnas.182426699;
RA   Surapureddi S., Yu S., Bu H., Hashimoto T., Yeldandi A.V.,
RA   Kashireddy P., Cherkaoui-Malki M., Qi C., Zhu Y.-J., Rao M.S.,
RA   Reddy J.K.;
RT   "Identification of a transcriptionally active peroxisome proliferator-
RT   activated receptor alpha-interacting cofactor complex in rat liver and
RT   characterization of PRIC285 as a coactivator.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:11836-11841(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), FUNCTION, INTERACTION
RP   WITH PPARG, TISSUE SPECIFICITY, DOMAIN, AND VARIANTS ASN-788;
RP   ARG-1123; LEU-2016 AND GLU-2049.
RX   PubMed=16239304; DOI=10.1210/en.2005-0450;
RA   Tomaru T., Satoh T., Yoshino S., Ishizuka T., Hashimoto K., Monden T.,
RA   Yamada M., Mori M.;
RT   "Isolation and characterization of a transcriptional cofactor and its
RT   novel isoform that bind the DNA-binding domain of peroxisome
RT   proliferator-activated receptor gamma.";
RL   Endocrinology 147:377-388(2006).
RN   [3]
RP   PARTIAL NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND
RP   VARIANTS VARIANTS ASN-788; ARG-1123; LEU-2016 AND GLU-2049.
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XIX.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:347-355(2000).
RN   [4]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=11780052; DOI=10.1038/414865a;
RA   Deloukas P., Matthews L.H., Ashurst J.L., Burton J., Gilbert J.G.R.,
RA   Jones M., Stavrides G., Almeida J.P., Babbage A.K., Bagguley C.L.,
RA   Bailey J., Barlow K.F., Bates K.N., Beard L.M., Beare D.M.,
RA   Beasley O.P., Bird C.P., Blakey S.E., Bridgeman A.M., Brown A.J.,
RA   Buck D., Burrill W.D., Butler A.P., Carder C., Carter N.P.,
RA   Chapman J.C., Clamp M., Clark G., Clark L.N., Clark S.Y., Clee C.M.,
RA   Clegg S., Cobley V.E., Collier R.E., Connor R.E., Corby N.R.,
RA   Coulson A., Coville G.J., Deadman R., Dhami P.D., Dunn M.,
RA   Ellington A.G., Frankland J.A., Fraser A., French L., Garner P.,
RA   Grafham D.V., Griffiths C., Griffiths M.N.D., Gwilliam R., Hall R.E.,
RA   Hammond S., Harley J.L., Heath P.D., Ho S., Holden J.L., Howden P.J.,
RA   Huckle E., Hunt A.R., Hunt S.E., Jekosch K., Johnson C.M., Johnson D.,
RA   Kay M.P., Kimberley A.M., King A., Knights A., Laird G.K., Lawlor S.,
RA   Lehvaeslaiho M.H., Leversha M.A., Lloyd C., Lloyd D.M., Lovell J.D.,
RA   Marsh V.L., Martin S.L., McConnachie L.J., McLay K., McMurray A.A.,
RA   Milne S.A., Mistry D., Moore M.J.F., Mullikin J.C., Nickerson T.,
RA   Oliver K., Parker A., Patel R., Pearce T.A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Prathalingam S.R., Plumb R.W., Ramsay H.,
RA   Rice C.M., Ross M.T., Scott C.E., Sehra H.K., Shownkeen R., Sims S.,
RA   Skuce C.D., Smith M.L., Soderlund C., Steward C.A., Sulston J.E.,
RA   Swann R.M., Sycamore N., Taylor R., Tee L., Thomas D.W., Thorpe A.,
RA   Tracey A., Tromans A.C., Vaudin M., Wall M., Wallis J.M.,
RA   Whitehead S.L., Whittaker P., Willey D.L., Williams L., Williams S.A.,
RA   Wilming L., Wray P.W., Hubbard T., Durbin R.M., Bentley D.R., Beck S.,
RA   Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 20.";
RL   Nature 414:865-871(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1526-2649 (ISOFORMS 1/2/3).
RC   TISSUE=Spleen;
RA   Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.;
RT   "The nucleotide sequence of a long cDNA clone isolated from human
RT   spleen.";
RL   Submitted (JAN-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2194-2649 (ISOFORMS 1/2/3).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1006, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1006, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [11]
RP   FUNCTION, INTERACTION WITH PPARG AND THRAP3, AND SUBCELLULAR LOCATION.
RX   PubMed=23525231; DOI=10.1210/me.2012-1332;
RA   Katano-Toki A., Satoh T., Tomaru T., Yoshino S., Ishizuka T.,
RA   Ishii S., Ozawa A., Shibusawa N., Tsuchiya T., Saito T., Shimizu H.,
RA   Hashimoto K., Okada S., Yamada M., Mori M.;
RT   "THRAP3 interacts with HELZ2 and plays a novel role in adipocyte
RT   differentiation.";
RL   Mol. Endocrinol. 27:769-780(2013).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Colon carcinoma;
RX   PubMed=24129315; DOI=10.1074/mcp.O113.027870;
RA   Guo A., Gu H., Zhou J., Mulhern D., Wang Y., Lee K.A., Yang V.,
RA   Aguiar M., Kornhauser J., Jia X., Ren J., Beausoleil S.A., Silva J.C.,
RA   Vemulapalli V., Bedford M.T., Comb M.J.;
RT   "Immunoaffinity enrichment and mass spectrometry analysis of protein
RT   methylation.";
RL   Mol. Cell. Proteomics 13:372-387(2014).
CC   -!- FUNCTION: Helicase that acts as a transcriptional coactivator for
CC       a number of nuclear receptors including PPARA, PPARG, THRA, THRB
CC       and RXRA. {ECO:0000269|PubMed:16239304,
CC       ECO:0000269|PubMed:23525231}.
CC   -!- SUBUNIT: Interacts with PPARA (via DNA-binding domain) and PPARG;
CC       the interaction stimulates the transcriptional activity of PPARA
CC       and PPARG. Interacts with THRAP3; the interaction is direct and
CC       HELZ2 and THRAP3 synergistically enhance the transcriptional
CC       activity of PPARG. It is probably part of the peroxisome
CC       proliferator activated receptor alpha interacting complex (PRIC).
CC       {ECO:0000269|PubMed:16239304, ECO:0000269|PubMed:23525231}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:23525231}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=PDIP1-beta;
CC         IsoId=Q9BYK8-1; Sequence=Displayed;
CC         Note=More abundantly expressed than isoform 2.;
CC       Name=2; Synonyms=PDIP1-alpha;
CC         IsoId=Q9BYK8-2; Sequence=VSP_007297, VSP_007298;
CC       Name=3;
CC         IsoId=Q9BYK8-4; Sequence=VSP_017377, VSP_017378;
CC         Note=Incomplete sequence. No experimental confirmation
CC         available.;
CC   -!- TISSUE SPECIFICITY: Expressed in various tissues including heart,
CC       pancreas, skeletal muscle, colon, spleen, liver, kidney, lung,
CC       peripheral blood and placenta. {ECO:0000269|PubMed:16239304}.
CC   -!- DOMAIN: Contains 5 Leu-Xaa-Xaa-Leu-Leu (LXXLL) motifs. These
CC       motifs are not required for interaction with PPARG.
CC       {ECO:0000269|PubMed:16239304}.
CC   -!- SIMILARITY: Belongs to the DNA2/NAM7 helicase family.
CC       {ECO:0000305}.
CC   -!- CAUTION: PubMed:12189208 experiments have been carried out partly
CC       in rat and partly in human. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB70969.1; Type=Frameshift; Positions=2206; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF517673; AAM74197.1; -; mRNA.
DR   EMBL; AB201715; BAE46995.1; -; mRNA.
DR   EMBL; AB051556; BAB21860.2; -; mRNA.
DR   EMBL; AL121829; CAI95749.1; -; Genomic_DNA.
DR   EMBL; AK074171; BAB84997.1; -; mRNA.
DR   EMBL; AK055611; BAB70969.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS13527.1; -. [Q9BYK8-2]
DR   CCDS; CCDS33508.1; -. [Q9BYK8-1]
DR   RefSeq; NP_001032412.2; NM_001037335.2. [Q9BYK8-1]
DR   RefSeq; NP_208384.3; NM_033405.3. [Q9BYK8-2]
DR   UniGene; Hs.517180; -.
DR   ProteinModelPortal; Q9BYK8; -.
DR   BioGrid; 124528; 10.
DR   IntAct; Q9BYK8; 1.
DR   STRING; 9606.ENSP00000417401; -.
DR   iPTMnet; Q9BYK8; -.
DR   PhosphoSitePlus; Q9BYK8; -.
DR   BioMuta; HELZ2; -.
DR   DMDM; 317373591; -.
DR   EPD; Q9BYK8; -.
DR   MaxQB; Q9BYK8; -.
DR   PaxDb; Q9BYK8; -.
DR   PeptideAtlas; Q9BYK8; -.
DR   PRIDE; Q9BYK8; -.
DR   Ensembl; ENST00000427522; ENSP00000393257; ENSG00000130589. [Q9BYK8-2]
DR   Ensembl; ENST00000467148; ENSP00000417401; ENSG00000130589. [Q9BYK8-1]
DR   GeneID; 85441; -.
DR   KEGG; hsa:85441; -.
DR   UCSC; uc002yfl.2; human. [Q9BYK8-1]
DR   CTD; 85441; -.
DR   DisGeNET; 85441; -.
DR   GeneCards; HELZ2; -.
DR   HGNC; HGNC:30021; HELZ2.
DR   HPA; HPA051267; -.
DR   MIM; 611265; gene.
DR   neXtProt; NX_Q9BYK8; -.
DR   OpenTargets; ENSG00000130589; -.
DR   eggNOG; KOG1804; Eukaryota.
DR   eggNOG; KOG2102; Eukaryota.
DR   eggNOG; COG0557; LUCA.
DR   eggNOG; COG1112; LUCA.
DR   GeneTree; ENSGT00800000124068; -.
DR   HOGENOM; HOG000231856; -.
DR   HOVERGEN; HBG080465; -.
DR   InParanoid; Q9BYK8; -.
DR   OMA; PRHPQHY; -.
DR   OrthoDB; EOG091G01CH; -.
DR   PhylomeDB; Q9BYK8; -.
DR   Reactome; R-HSA-1368082; RORA activates gene expression.
DR   Reactome; R-HSA-1368108; BMAL1:CLOCK,NPAS2 activates circadian gene expression.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression.
DR   Reactome; R-HSA-2032785; YAP1- and WWTR1 (TAZ)-stimulated gene expression.
DR   Reactome; R-HSA-2151201; Transcriptional activation of mitochondrial biogenesis.
DR   Reactome; R-HSA-2426168; Activation of gene expression by SREBF (SREBP).
DR   Reactome; R-HSA-381340; Transcriptional regulation of white adipocyte differentiation.
DR   Reactome; R-HSA-400206; Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha).
DR   Reactome; R-HSA-400253; Circadian Clock.
DR   GeneWiki; PRIC285; -.
DR   GenomeRNAi; 85441; -.
DR   PRO; PR:Q9BYK8; -.
DR   Proteomes; UP000005640; Chromosome 20.
DR   Bgee; ENSG00000130589; -.
DR   Genevisible; Q9BYK8; HS.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0004386; F:helicase activity; IEA:UniProtKB-KW.
DR   GO; GO:0030374; F:ligand-dependent nuclear receptor transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0044255; P:cellular lipid metabolic process; TAS:Reactome.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR031191; HELZ2.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR022966; RNase_II/R_CS.
DR   InterPro; IPR013087; Znf_C2H2_type.
DR   PANTHER; PTHR43788:SF2; PTHR43788:SF2; 1.
DR   SUPFAM; SSF50249; SSF50249; 4.
DR   SUPFAM; SSF52540; SSF52540; 4.
DR   SUPFAM; SSF57667; SSF57667; 1.
DR   PROSITE; PS00028; ZINC_FINGER_C2H2_1; 1.
PE   1: Evidence at protein level;
KW   Activator; Alternative splicing; ATP-binding; Complete proteome;
KW   DNA-binding; Helicase; Hydrolase; Metal-binding; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transcription; Transcription regulation; Zinc; Zinc-finger.
FT   CHAIN         1   2649       Helicase with zinc finger domain 2.
FT                                /FTId=PRO_0000058561.
FT   ZN_FING      40     64       C2H2-type; atypical.
FT   NP_BIND     544    551       ATP. {ECO:0000255}.
FT   NP_BIND    2174   2181       ATP. {ECO:0000255}.
FT   REGION      563   1059       Interaction with THRAP3.
FT                                {ECO:0000269|PubMed:23525231}.
FT   REGION     2135   2649       Interaction with THRAP3.
FT                                {ECO:0000269|PubMed:23525231}.
FT   MOTIF       667    670       DEAA box.
FT   MOTIF      1075   1079       LXXLL motif 1.
FT   MOTIF      1118   1122       LXXLL motif 2.
FT   MOTIF      1173   1177       LXXLL motif 3.
FT   MOTIF      2012   2016       LXXLL motif 4.
FT   MOTIF      2229   2233       LXXLL motif 5.
FT   COMPBIAS    968   1059       Ala-rich.
FT   MOD_RES    1006   1006       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    569       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12189208,
FT                                ECO:0000303|PubMed:16239304}.
FT                                /FTId=VSP_007297.
FT   VAR_SEQ       1    535       Missing (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_017377.
FT   VAR_SEQ     536    576       RVPPLLIYGPFGTGKTYTLAMASLEVIRRPETKVLICTHTN
FT                                -> LTSDSQTRAVLRGSSAGHTVGALADSTEAPSKKPMSSS
FT                                PSR (in isoform 3). {ECO:0000305}.
FT                                /FTId=VSP_017378.
FT   VAR_SEQ     570    576       LICTHTN -> MSSSPSR (in isoform 2).
FT                                {ECO:0000303|PubMed:12189208,
FT                                ECO:0000303|PubMed:16239304}.
FT                                /FTId=VSP_007298.
FT   VARIANT     788    788       S -> N (in dbSNP:rs438363).
FT                                {ECO:0000269|PubMed:11214970,
FT                                ECO:0000269|PubMed:12189208,
FT                                ECO:0000269|PubMed:16239304}.
FT                                /FTId=VAR_015597.
FT   VARIANT    1123   1123       H -> R (in dbSNP:rs310632).
FT                                {ECO:0000269|PubMed:11214970,
FT                                ECO:0000269|PubMed:12189208,
FT                                ECO:0000269|PubMed:16239304}.
FT                                /FTId=VAR_015598.
FT   VARIANT    1152   1152       S -> L (in dbSNP:rs35817585).
FT                                /FTId=VAR_047038.
FT   VARIANT    1308   1308       V -> L (in dbSNP:rs310631).
FT                                /FTId=VAR_047039.
FT   VARIANT    1381   1381       R -> K (in dbSNP:rs3810487).
FT                                /FTId=VAR_047040.
FT   VARIANT    1821   1821       L -> R (in dbSNP:rs3810486).
FT                                /FTId=VAR_047041.
FT   VARIANT    1889   1889       T -> A (in dbSNP:rs34980032).
FT                                /FTId=VAR_047042.
FT   VARIANT    2016   2016       P -> L (in dbSNP:rs3810485).
FT                                {ECO:0000269|PubMed:11214970,
FT                                ECO:0000269|PubMed:12189208,
FT                                ECO:0000269|PubMed:16239304}.
FT                                /FTId=VAR_015599.
FT   VARIANT    2049   2049       Q -> E (in dbSNP:rs3810483).
FT                                {ECO:0000269|PubMed:11214970,
FT                                ECO:0000269|PubMed:12189208,
FT                                ECO:0000269|PubMed:16239304}.
FT                                /FTId=VAR_015600.
FT   VARIANT    2170   2170       T -> M (in dbSNP:rs3810481).
FT                                /FTId=VAR_047043.
FT   CONFLICT    196    196       V -> A (in Ref. 2; BAE46995).
FT                                {ECO:0000305}.
FT   CONFLICT    327    329       FNR -> SNH (in Ref. 2; BAE46995).
FT                                {ECO:0000305}.
FT   CONFLICT    442    442       E -> G (in Ref. 2; BAE46995).
FT                                {ECO:0000305}.
FT   CONFLICT    836    836       G -> D (in Ref. 2; BAE46995).
FT                                {ECO:0000305}.
FT   CONFLICT   1873   1873       V -> A (in Ref. 2; BAE46995).
FT                                {ECO:0000305}.
FT   CONFLICT   2203   2203       G -> S (in Ref. 2; BAE46995).
FT                                {ECO:0000305}.
FT   CONFLICT   2383   2383       V -> A (in Ref. 2; BAE46995).
FT                                {ECO:0000305}.
FT   CONFLICT   2626   2626       F -> L (in Ref. 2; BAE46995).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2649 AA;  294651 MW;  419573D5AEE700D7 CRC64;
     MAVWEAEQLG GLQRGDLLTP PAPDGDGRTA PLGQPPGAQL YCPACLVTCH SQEAFENHCA
     SSEHAQMVAF DQALPWEHRS PPPGLSKFEL CPKPDLCEYG DACTKAHSAQ ELQEWVRRTQ
     AVELRGQAAW QDGLVPYQER LLAEYQRSSS EVLVLAETLD GVRVTCNQPL MYQAQERKTQ
     YSWTFAVHSE EPLLHVALLK QEPGADFSLV APGLPPGRLY ARGERFRVPS STADFQVGVR
     VQAASFGTFE QWVVFDFGRR PVLLQKLGLQ LGQGRRPGPC RNLALGHPEE MERWHTGNRH
     VVPGVERTAE QTALMAKYKG PALALEFNRS SVASGPISPT NYRQRMHQFL YEEEAAQQQL
     VAKLTLRGQV FLKTALQTPA LNMLFAPPGA LYAEVPVPSS LMPDTDQGFL LGRAVSTALV
     APVPAPDNTV FEVRLERRAS SEQALWLLLP ARCCLALGLQ PEARLVLEVQ FQIDPMTFRL
     WHQAVDTLPE EQLVVPDLPT CALPRPWSVP PLRRGNRKQE LAVALIAGWG PGDGRRVPPL
     LIYGPFGTGK TYTLAMASLE VIRRPETKVL ICTHTNSAAD IYIREYFHSH VSGGHPEATP
     LRVMYTDRPL SQTDPVTLQY CCLTDDRQAF RPPTRAELAR HRVVVTTTSQ ARELRVPVGF
     FSHILIDEAA QMLECEALTP LAYASHGTRL VLAGDHMQVT PRLFSVARAR AAEHTLLHRL
     FLCYQQETHE VARQSRLVFH ENYRCTDAIV SFISRHFYVA KGNPIHARGK VPPHPRHYPL
     MFCHVAGSPD RDMSMASWLN LAEIAQVVEK VQEAYNTWPS CWGGREQRCI CVVSHGAQVS
     ALRQELRRRD LGQVSVGSFE ILPGRQFRVV VLSTVHTCQS LLSPGALAPE FFTDARVLNT
     VLTRAQSQLV VVGDAVALCS FGACGKLWES FIRECVERHS VCPEGLSMEQ VEQGVAQRRR
     WPPRGTQAGA AGNWEAAPEP VGDLAEEQAA VVTAMVKAEP GDEALSPASR DITATTAQTE
     AAAAPAGDAV KEDVVPGACA AGAAAAAGVE STEAEDAEAD FWPWDGELNA DDAILRELLD
     ESQKVMVTVG EDGLLDTVAR PESLQQARLY ENLPPAALRK LLHAEPERYR HCSFVPETFE
     RASAIPLDDA SSGPIQVRGR LDCGMAFAGD EVLVQLLSGD KAPEGRLRGR VLGVLKRKRH
     ELAFVCRMDT WDPRIMVPIN GSVTKIFVAE LKDPSQVPIY SLRKGRLQRV GLERLTAEAR
     HSRLFWVQIV LWRQGFYYPL GIVREVLPEA STWEQGLRIL GLEYSLRVPP SDQATITKVL
     QKYHTELGRV AGRREDCRAF LTFTVDPQGA CNLDDALSVR DLGPRCEVAV HITDVASFVP
     RDGVLDVEAR RQGAAFYAPG REPVPMLPAS LCQDVLSLLP GRDRLAISLF LTMEKASGQL
     KSLRFAPSVV QSDRQLSYEE AEEVIRQHPG AGRELPARLD SVDACVVAAC YFSRLLRRHR
     LRSDCFYEQP DEDGTLGFRA AHIMVKEYMI QFNRLVAEFL VGSECTRTVT PLRWQPAPRS
     QQLKALCEKH GDRVPLSLHL GHHLHGGGGS PPDTRLHLLA SLWKQVQFAA RTQDYEQMVD
     LVTTDDMHPF LAPAGRDLRK ALERSAFGRC ARGHQQQGGH YSLQVDWYTW ATSPIRRYLD
     VVLQRQILLA LGHGGSAYSA RDIDGLCQAF SLQHALAQSY QRRARSLHLA VQLKAQPLDK
     LGFVVDVEAG SRCFRLLFPS NRETLPDPCP VPYGSLQLAE HPHALAGRPG LRLLWRRRVY
     SAQGSSPPLP LPGTVPDPHT LAVETALWKQ LLELVELQRW PEAAALIQEK GEASQRRELV
     QVQRSHCGHF LEVARELGSG DTLQVQLGTS LQHGFLVPSP QLWTVAPGFS LCLEHVERPG
     DCFSGRVYRA PRDRYRDVDE YACVWEPFCA LESATGAVAE NDSVTLQHLS VSWEASRTPQ
     GQLQGAFRLE AAFLEENCAD INFSCCYLCI RLEGLPAPTA SPRPGPSSLG PGLNVDPGTY
     TWVAHGQTQD WDQERRADRQ EAPRRVHLFV HHMGMEKVPE EVLRPGTLFT VELLPKQLPD
     LRKEEAVRGL EEASPLVTSI ALGRPVPQPL CRVIPSRFLE RQTYNIPGGR HKLNPSQNVA
     VREALEKPFT VIQGPPGTGK TIVGLHIVFW FHKSNQEQVQ PGGPPRGEKR LGGPCILYCG
     PSNKSVDVLA GLLLRRMELK PLRVYSEQAE ASEFPVPRVG SRKLLRKSPR EGRPNQSLRS
     ITLHHRIRQA PNPYSSEIKA FDTRLQRGEL FSREDLVWYK KVLWEARKFE LDRHEVILCT
     CSCAASASLK ILDVRQILVD EAGMATEPET LIPLVQFPQA EKVVLLGDHK QLRPVVKNER
     LQNLGLDRSL FERYHEDAHM LDTQYRMHEG ICAFPSVAFY KSKLKTWQGL RRPPSVLGHA
     GKESCPVIFG HVQGHERSLL VSTDEGNENS KANLEEVAEV VRITKQLTLG RTVEPQDIAV
     LTPYNAQASE ISKALRREGI AGVAVSSITK SQGSEWRYVL VSTVRTCAKS DLDQRPTKSW
     LKKFLGFVVD PNQVNVAVTR AQEGLCLIGD HLLLRCCPLW RSLLDFCEAQ QTLVPAGQVR
     VCRRPTMPS
//
